UPDATED: Precision hails phase 1/2 data as proof it could deliver the first approved off-the-shelf CAR-T AstraZeneca trots out Evusheld data to expand the COVID preventive drug into the treatment arena Teladoc hit with lawsuit alleging it misled investors after 'significant losses' As monkeypox cases rise, BD pairs up with Spain-based CerTest for diagnostic Weight watcher: Innovent catching up with Lilly, Novo Nordisk thanks to phase 2 obesity data Lilly, Novo Nordisk's weight loss meds could replace surgery for obesity patients: specialist AHA: Nonprofit hospitals provided community benefits 9 times higher than 2019 tax exemptions FDA slaps Class I label on Medtronic latest heart pump recall With Keytruda leading the way, Merck tallies 80-plus potential oncology approvals by 2028 Moderna eyes fall vaccine season for omicron booster after phase 2/3 success Residents of Republican counties more likely to die of COVID-19 regardless of own political beliefs, study finds Ginkgo Bioworks picks up Bitome's AI to bolster its cell engineering platform Featured Story | By Max Bayer Gene editing biotech Precision BioSciences is touting phase 1/2 results as proof it could bring the first allogeneic CAR-T drug to market. The promising, albeit early, data from the study found that 100% of evaluable patients whose cancer had relapsed had responded to the treatment. read more |
| |
|---|
|
Top Stories By Zoey Becker AstraZeneca is back in the COVID-19 game with new data for its antibody cocktail, Evusheld. While it's existing authorizations cover the prophylactic setting, the latest results from the Big Pharma putsthe drug in contention as a treatment for patients with mild-to-moderate disease. read more By Heather Landi Teladoc is facing a lawsuit alleging the company misled investors about the company’s business, operations and prospects as the virtual care company's stock price has plunged in the past year. read more By Conor Hale The project aims to have CerTest’s CE-marked test operate on the BD MAX automated PCR system. read more By James Waldron Innovent is catching up with the likes of Eli Lilly and Novo Nordisk as the Chinese pharma’s own obesity drug passes strong results in a phase 2 trial. A placebo-controlled trial of the drug, mazdutide, in 230 Chinese participants met the primary endpoint of a percentage change in baseline body weight at week 24. read more By Kevin Dunleavy Tirzepatide weight loss data presented this week by Eli Lilly are so compelling that the drug and Novo Nordisk's Wegovy could in many circumstances replace sleeve bariatric and gastric bypass surgeries—often seen as last resorts for those who are morbidly obese. That is the belief of a key opinion leading obesity specialist who was consulted by SVB Securities. read more By Dave Muoio An average 13.9% of hospitals’ total expenses went toward community benefits in 2019, according to a recent report from the American Hospital Association and Ernst & Young. read more By Andrea Park A year after being laid to rest, the troubled HeartWare Ventricular Assist Device system is causing problems for Medtronic. read more By Angus Liu Before the introduction of Keytruda, Merck & Co. wasn’t exactly a major oncology player. Now holding the world’s best-selling cancer drug, the New Jersey pharma looks to consolidate its leadership with more than 80 potential cancer approvals by 2028. read more By James Waldron Moderna hopes that the successful readout from a phase 2/3 trial of its omicron-targeting COVID-19 shot means the booster will be ready for people’s arms by the late summer. read more By Anastassia Gliadkovskaya A lack of implementation or compliance with public health measures "played a significant role" in mortality, which was likely driven by individual political beliefs. read more By Andrea Park Ginkgo Bioworks has acquired certain assets from Bitome, which is developing machine learning technology to track how well individual cell lines are performing throughout the programming process. read more | 